CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell?
The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, CRSP is yet to record product sales.
2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows
With that in mind, let's consider two stocks that haven't performed well recently and are now near their 52-week lows but ...
Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts
If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Lowered to $85.00 at Bank of America
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target lowered by Bank of America from $98.00 to $85.00 in ...
Editas And Intellia: Strategic Shifts And Long-Term Investment Potential
A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.
Check Out What Whales Are Doing With CRSP
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you ...
Nordea Investment Management AB Increases Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)
Nordea Investment Management AB grew its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 4.4% in the ...
Intellia Therapeutics: Buying The Path To Commercialization
Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for ...
Nasdaq24d
CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors
In the latest market close, CRISPR Therapeutics AG (CRSP ... The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of ...